Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin

Abstract

Infantile fibrosarcoma is a non-rhabdomyosarcoma soft-tissue sarcoma that occurs in infancy and which has a relatively good prognosis. A vincristine and dactinomycin (VA) regimen has been shown to be effective, although the duration of chemotherapy has not been well defined. We describe the case of a 4-month-old boy with a mass at the left dorsum of the foot who was diagnosed with infantile fibrosarcoma after resection of the tumor, the margin of which was macroscopically positive. VA treatment was carried out with careful monitoring of response and adverse effects. Pancytopenia was seen during the second cycle, and therapy was reduced thereafter. The treatment was continued for 38 weeks (12 cycles). There was no functional impairment, and no evidence of recurrence at 18 months after therapy.

Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

“…Very recently, a case report was done of infantile fibrosarcoma treated by adjuvant therapy after excision, using vincristine and dactinomycin, where the duration of chemotherapy was determined according to tumor response. At the end, there was no functional impairment and no evidence of recurrence at 18 months after therapy [ 37 ].…”

Fibrosarkoma Infantil pada Retroperitoneal : Laporan Kasus

“…Eksisi lokal luas dengan batas negatif dapat menjadi pilihan pertama untuk membuang tumor, karena batas pasca operasi dapat menjadi faktor prognostik pada tumor ini 2 . Penelitian Eropa menyimpulkan Vincristine dan Dactinomycin (VA) dapat digunakan sebagai pilihan kemoterapi pasca operasia 10 . Prognosis kasus ini pada umumnya baik 5 .…”

Therapeutic value of steroidal alkaloids in cancer: Current trends and future perspectives

“…For instance, the FDA has approved vincristine, which is isolated from the leaves of the Madagascar periwinkle Catharanthus roseus (L.) G. Don (formerly Vinca rosea L.), for cancer treatment . Dactinomycin, produced by Streptomyces parvulus , is administered as an antineoplastic antibiotic for the treatment of Kaposi's sarcoma, infantile fibrosarcoma and testicular cancer . In 2005, paclitaxel (isolated from the bark of the Pacific yew ( Taxus brevifolia Nutt.)…”

“…158 Dactinomycin, produced by Streptomyces parvulus, is administered as an antineoplastic antibiotic for the treatment of Kaposi's sarcoma, infantile fibrosarcoma and testicular cancer. [159][160][161] In 2005, paclitaxel (isolated from the bark of the Pacific yew (Taxus brevifolia Nutt.) was approved by the FDA for use in the United States for the treatment of pancreatic, breast and non-small cell lung cancers.…”